Program
Pyridoxal Phosphate
Also written as “Pyridoxal 5'-Phosphate”, “(MC-1) Pyridoxal 5'-phosphate” and “(MC-1) Pyridoxal-5'-phosphate”.
Its studies are mostly in Myocardial Ischemia · Tardive Dyskinesia, led by Medicure.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Medicure | 52 open or running | phase 3since Nov 20, 2006 | Sep 8, 2005 | Sep 2027phase 3 · NCT04706013 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 8, 2005First study: phase 2 study in Myocardial IschemiaFirst studyNCT00157716 · 900 enrolled · United States, Canada
- Nov 20, 2006Phase 3 study in Myocardial IschemiaNCT00402506 · 3,000 enrolled · United States, Canada
- Jun 8, 2009Phase 2 study in Tardive DyskinesiaNCT00917293 · 53 enrolled · Canada, India
- Jan 8, 2021Phase 3 study in Pyridox(am)Ine 5'-Phosphate Oxidase DeficiencyNCT04706013 · 15 enrolled · United States, Australia
- Oct 28, 2026Phase 3 study in Pyridox(am)Ine 5'-Phosphate Oxidase DeficiencyNCT07928388 · 10 planned · United States, Australia
Ahead
- Sep 2027Primary completion: phase 3 study in Pyridox(am)Ine 5'-Phosphate Oxidase DeficiencyNCT04706013
- Jul 15, 2029Primary completion: phase 3 study in Pyridox(am)Ine 5'-Phosphate Oxidase DeficiencyNCT07928388
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07928388Pyridox(am)Ine 5'-Phosphate Oxidase Deficiency · United States, Australia | 3 | Recruiting | Jul 15, 2029 | 10 |
| NCT04706013Pyridox(am)Ine 5'-Phosphate Oxidase Deficiency · United States, Australia | 3 | Active, not recruiting | Sep 2027 | 15 |
| NCT00917293Tardive Dyskinesia · Canada, India | 2 | Terminated | Aug 2012 | 53 |
| NCT00402506Myocardial Ischemia · United States, Canada | 3 | Completed | 3,000 | |
| NCT00157716Myocardial Ischemia · United States, Canada | 2 | Completed | 900 |
How it is read
Names in the registry
- “Pyridoxal 5'-Phosphate”, 2 entries
- “Pyridoxal Phosphate”, 1 entry
- “(MC-1) Pyridoxal 5'-phosphate”, 1 entry
- “(MC-1) Pyridoxal-5'-phosphate”, 1 entry
Conditions, from the studies’ own filings
- Myocardial Ischemia, 2 studies
- Tardive Dyskinesia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.